Clinical trial
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid…
NCT00003926 · Masonic Cancer Center, University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00003926 |
|---|---|
| Title | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors |
| Official title | A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma |
| Intervention type | Drug, Procedure |
| Interventions | amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC) |
| Enrollment | 13 |
| Start date | Nov 1, 1998 |
| Primary completion | Aug 1, 2002 |
| Completion | Aug 1, 2003 |
| First posted | May 2, 2003 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: